Lidoderm Shows Promise in Treating Carpal Tunnel Syndrome

JANUARY 01, 2006
Susan Farley

A pilot study of Endo Pharmaceuticals' topical analgesic patch, lidocaine patch 5% (Lidoderm), showed a significant reduction in pain intensity, as well as a high satisfaction level among patients using the patch. Twenty patients treated with Lidoderm achieved a 41.5% reduction in mean pain intensity as measured by the Brief Pain Inventory. Another 20 patients received a single corticosteroid injection into the carpal tunnel and achieved a 43.8% reduction in pain intensity. Results also showed that 80% of patients treated with Lidoderm reported being "satisfied" or "very satisfied" with the treatment; investigators noted improvements in 88% of their patients. Among patients in the injection group, 59% reported being "satisfied" or "very satisfied" with their treatment, and investigators noted an overall 74% improvement in these patients. Study author Srinivas Nalamachu, MD, of the University of Medicine and Biosciences in Kansas City, Mo, commented, "We are excited to find a noninvasive, topical patch appeared to alleviate these patients' carpal-tunnel-syndrome-related pain." These results still need to be confirmed in a larger, double-blind, placebo-controlled study.

Ms. Farley is a freelance medical writer based in Wakefield, RI.



SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.